Vaxcyte Capex To Depreciation from 2010 to 2024

PCVX Stock  USD 86.53  0.32  0.37%   
Vaxcyte Capex To Depreciation yearly trend continues to be fairly stable with very little volatility. Capex To Depreciation is likely to outpace its year average in 2024. Capex To Depreciation is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. View All Fundamentals
 
Capex To Depreciation  
First Reported
2010-12-31
Previous Quarter
6.67358175
Current Value
7.01
Quarterly Volatility
1.87934039
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 66.1 M, Interest Expense of 0.0 or Selling General Administrative of 63.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.16. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
  
Check out the analysis of Vaxcyte Correlation against competitors.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Latest Vaxcyte's Capex To Depreciation Growth Pattern

Below is the plot of the Capex To Depreciation of Vaxcyte over the last few years. It is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. Vaxcyte's Capex To Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
Capex To Depreciation10 Years Trend
Slightly volatile
   Capex To Depreciation   
       Timeline  

Vaxcyte Capex To Depreciation Regression Statistics

Arithmetic Mean2.36
Geometric Mean1.91
Coefficient Of Variation79.72
Mean Deviation1.20
Median1.96
Standard Deviation1.88
Sample Variance3.53
Range6.3741
R-Value0.44
Mean Square Error3.08
R-Squared0.19
Significance0.10
Slope0.18
Total Sum of Squares49.45

Vaxcyte Capex To Depreciation History

2024 7.01
2023 6.67
2022 0.64
2021 1.9
2020 0.82
2019 0.97
2018 1.71

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Capex To Depreciation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Depreciation 6.67  7.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.